Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?

Affiliations

¹ Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Electronic address: andrea.casadei@irst.emr.it.
² Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Free article

Comment

A Casadei Gardini et al. Ann Oncol. 2017.

Free article

. 2017 Oct 1;28(10):2620.

doi: 10.1093/annonc/mdx291.

¹ Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Electronic address: andrea.casadei@irst.emr.it.
² Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

No abstract available

Comment on

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Ott PA, et al. Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029. Ann Oncol. 2017. PMID: 28453692 Free PMC article. Clinical Trial.